• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MEFIB vs. MAST and FAST: Not a competition but useful tools.

作者信息

Noureddin Mazen, Harrison Stephen A, Alkhouri Naim

机构信息

Houston Methodist Hospital, Houston, Texas, United States; Houston Research Institute, Houston, Texas, United States.

Pinnacle Research, San Antonio, Texas, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

出版信息

J Hepatol. 2024 Jan;80(1):e35-e36. doi: 10.1016/j.jhep.2022.10.020. Epub 2022 Nov 10.

DOI:10.1016/j.jhep.2022.10.020
PMID:36370950
Abstract
摘要

相似文献

1
MEFIB vs. MAST and FAST: Not a competition but useful tools.MEFIB与MAST和FAST：并非竞争关系，而是实用工具。
J Hepatol. 2024 Jan;80(1):e35-e36. doi: 10.1016/j.jhep.2022.10.020. Epub 2022 Nov 10.
2
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.MEFIB、MAST 和 FAST 检测非酒精性脂肪性肝病患者 2 期及以上纤维化的头对头比较。
J Hepatol. 2022 Dec;77(6):1482-1490. doi: 10.1016/j.jhep.2022.07.020. Epub 2022 Aug 13.
3
MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.MEFIB-Index 和 MAST-Score 在代谢相关脂肪性肝病肝失代偿评估中的应用：个体参与者数据荟萃分析。
Aliment Pharmacol Ther. 2023 Nov;58(9):856-865. doi: 10.1111/apt.17707. Epub 2023 Sep 11.
4
Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.磁共振弹性成像联合 Fibrosis-4 与 FibroScan-天门冬氨酸氨基转移酶在非酒精性脂肪性肝炎相关纤维化药物治疗候选者中的检测。
Hepatology. 2022 Mar;75(3):661-672. doi: 10.1002/hep.32145. Epub 2021 Dec 15.
5
Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.使用磁共振弹性成像结合纤维化-4指数和磁共振成像-天冬氨酸转氨酶评分评估匹伐贝特对伴有高甘油三酯血症的代谢功能障碍相关脂肪性肝病的影响。
JGH Open. 2023 Dec 11;7(12):959-965. doi: 10.1002/jgh3.13012. eCollection 2023 Dec.
6
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.磁共振弹性成像联合纤维化-4 对非酒精性脂肪性肝病中显著纤维化的验证。
J Gastroenterol Hepatol. 2022 Sep;37(9):1726-1731. doi: 10.1111/jgh.15893. Epub 2022 Jun 3.
7
Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease.磁共振弹性成像及MEFIB指数在预测非酒精性脂肪性肝病风险人群和患者肝脏相关结局及死亡率方面的预后价值。
Therap Adv Gastroenterol. 2022 Apr 29;15:17562848221093869. doi: 10.1177/17562848221093869. eCollection 2022.
8
Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease.影像学检查在临床试验和非酒精性脂肪性肝病临床管理中的作用。
Clin Liver Dis. 2023 May;27(2):363-372. doi: 10.1016/j.cld.2023.01.020. Epub 2023 Mar 9.
9
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.磁共振弹性成像肝硬度值和 MEFIB 指数与非酒精性脂肪性肝病肝脏相关结局的关系：一项个体参与者的系统评价和荟萃分析。
Gastroenterology. 2022 Oct;163(4):1079-1089.e5. doi: 10.1053/j.gastro.2022.06.073. Epub 2022 Jul 2.
10
M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.在诊断活动性纤维化非酒精性脂肪性肝炎方面，M-PAST评分优于MAST评分。
Hepatol Res. 2023 Sep;53(9):844-856. doi: 10.1111/hepr.13927. Epub 2023 Jun 15.

引用本文的文献

1
Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.用于识别有代谢功能障碍相关脂肪性肝炎风险患者的非侵入性评估
Gastroenterol Hepatol (N Y). 2024 Nov;20(11):672-677.
2
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics.21世纪的非酒精性脂肪性肝病：关于其发病机制、诊断和治疗的当前知识
Biomedicines. 2024 Apr 9;12(4):826. doi: 10.3390/biomedicines12040826.
3
Identification of high-risk subjects in nonalcoholic fatty liver disease.非酒精性脂肪性肝病高危人群的识别。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S196-S206. doi: 10.3350/cmh.2022.0431. Epub 2022 Dec 5.